People listening supportively in an aspergillosis peer-support group, with different paths representing individual patient journeys.

Your Story Matters—but It Is Not Someone Else’s Future

People listening supportively in an aspergillosis peer-support group, with different paths representing individual patient journeys.
Every person’s experience of aspergillosis is valuable, but it cannot predict another patient’s future.

Being diagnosed with aspergillosis can be frightening. Many people turn to support groups hoping to meet others who understand, learn what treatment is like and discover how people manage everyday life.

Hearing from someone who has lived through the same illness can provide something that medical information alone cannot: recognition, practical experience and the reassurance that you are not facing it alone.

But there is an important distinction between sharing an experience and predicting another person’s future.

“This happened to me” can be helpful.
“This is what you have ahead of you” may not be true.

Aspergillosis does not follow one path

The word aspergillosis covers several very different conditions. These include allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), Aspergillus bronchitis, aspergilloma and invasive aspergillosis.

They do not have the same causes, treatments or likely outcomes. The US Centers for Disease Control and Prevention notes that different forms of aspergillosis have different symptoms and treatments.

Even people with the same form of aspergillosis can have very different experiences. Their health may be influenced by:

  • the extent of their lung disease;
  • asthma, bronchiectasis or another underlying condition;
  • immune function and other health problems;
  • how early the disease was recognised;
  • response to antifungal or other treatment;
  • side effects and tolerance of medicines;
  • access to specialist care.

One person’s course—whether difficult or relatively straightforward—cannot reliably tell us what will happen to another.

For more information about how the different conditions compare, see our guide to the different forms of aspergillosis.

Why support groups can sometimes appear frightening

Support groups perform an enormously valuable role. Research across a range of health conditions shows that peer support can reduce isolation, provide practical knowledge and help people cope with illness.

However, the conversations in a support group do not necessarily represent everyone living with the condition.

People are particularly likely to seek help when they are newly diagnosed, experiencing symptoms, having treatment difficulties or feeling worried. Those who are stable or getting on with their lives may have less reason to post regularly. This can make the most complicated experiences especially visible.

Several people describing serious difficulties does not necessarily mean that everyone—or even most people—with the condition will experience the same course.

This does not make those difficult stories any less real. It simply means that they should not be treated as a forecast for somebody else.

Difficult experiences deserve to be heard

People who have endured years of illness may want to protect others from being unprepared. A warning that sounds pessimistic may come from kindness, frustration or the wish to ensure that another patient is taken seriously.

Nobody should feel pressured to make a difficult experience sound positive. Support groups must remain places where people can speak honestly about fear, deterioration, treatment failures and loss.

But honesty also includes acknowledging uncertainty:

“My illness developed in this way, but yours may not.”

That small qualification can make a great difference to somebody who has only just been diagnosed.

Sharing without predicting

Helpful ways to introduce a personal experience include:

  • “This was my experience, although yours may be different.”
  • “I have the same diagnosis, but I also have other lung conditions.”
  • “This happened to me, so it may be worth asking your doctor about.”
  • “Some people experience this, but not everyone does.”
  • “Ask your clinical team what they expect in your particular case.”

Try to avoid statements such as:

  • “This is what you have ahead of you.”
  • “It will inevitably get worse.”
  • “That treatment never works.”
  • “You will end up in the same position as me.”

The same principle applies to reassuring stories. One person doing very well does not guarantee that another person will have the same result. Peer support should offer experience, companionship and useful questions—not certainty that no individual can provide.

For people who are newly diagnosed

If the stories you encounter feel overwhelming, remember:

  • the person speaking may have a different form of aspergillosis;
  • they may have additional illnesses or a more complicated clinical history;
  • support-group discussions may contain a greater proportion of people currently experiencing problems;
  • treatments and clinical knowledge change over time;
  • your own healthcare team has information about your tests, scans, medical history and response to treatment.

It is reasonable to ask your healthcare team:

  • Which form of aspergillosis do I have?
  • How severe does it appear to be?
  • What is the purpose of my treatment?
  • What improvement or stability are you hoping to achieve?
  • What will you monitor?
  • Are there particular warning signs I should know about?

These questions can provide more useful information about your likely course than another person’s experience alone.

Making space for every story

A healthy support community needs people who are struggling, people who are improving and people whose condition is stable. It needs realism, but it also needs hope—and neither should be manufactured.

Your experience matters. Sharing it may help someone feel understood, recognise a problem or ask an important question.

But it remains your story, not their prognosis.

The most supportive message we can offer may be:

“I cannot tell you what your future holds, but you do not have to face the uncertainty alone.”

If you would like to meet other people affected by aspergillosis, learn more about our patient support groups and meetings.

Further reading

Research reviews describe both the important benefits and possible challenges of peer support, including emotional support, practical knowledge and reduced isolation, alongside possible risks such as distress spreading between members.

This article provides general information and is not a prediction of any individual’s health or a substitute for advice from their healthcare team.


Damp, mould and health in 2026: what we know, what has changed and what people can do

Infographic summarising 2026 evidence on damp, mould and health, including respiratory risks, mental health effects, vulnerable groups and practical steps for people living in damp homes.
What current evidence says about damp and mould exposure, who may be most at risk, and what people can do to make homes healthier.
Research Perspectives | Last reviewed: 15 July 2026

The evidence that damp and mouldy buildings can damage health is now well established.
New research is moving the field forward by measuring the fungi people actually breathe,
examining long-term exposure and mental health, and asking how homes can become more
energy efficient without trapping moisture.

The state of play

Damp and mould are no longer regarded simply as cosmetic housing problems. The 
World Health Organization guidelines on indoor dampness and mould
concluded that occupants of damp or mouldy buildings have increased risks of respiratory
symptoms, respiratory infections and worsening asthma.

Since then, large reviews and newer studies have continued to associate damp or mouldy
homes with:

  • the development and worsening of asthma;
  • wheeze, cough and breathlessness;
  • allergic rhinitis and fungal sensitisation;
  • respiratory infections, particularly in children;
  • hypersensitivity pneumonitis in susceptible people;
  • fungal disease in a smaller number of clinically vulnerable people;
  • stress, anxiety and poorer mental wellbeing.

These findings describe increased risks across populations. They do not mean that every
person living in a damp home will become ill, or that every symptom occurring in a mouldy
property was necessarily caused by mould.

Nevertheless, the overall evidence is sufficiently strong that public-health advice is to
prevent persistent dampness and remediate mould promptly. Current
UK Government guidance on the health risks of damp and mould
also makes clear that landlords should respond to the presence of damp and mould rather than
waiting for tenants to provide medical proof.

How our understanding has changed

Before 2000: concern but limited measurement

Doctors and housing researchers had long observed that people in damp buildings reported
more respiratory symptoms, but studies used many different definitions of dampness and
mould.

2009: an international evidence benchmark

The WHO reviewed the available evidence and concluded that preventing or minimising
persistent dampness and microbial growth was the most important protective measure.

2010s: stronger epidemiological evidence

Systematic reviews found consistent associations between visible dampness or mould and
asthma, wheeze, cough, respiratory infections and allergic symptoms. A widely cited
review by Mendell and colleagues
helped establish the modern evidence base.

2022–25: damp housing becomes a major UK policy issue

The death of two-year-old Awaab Ishak after prolonged exposure to mould in social housing
transformed public understanding and accelerated legal reform. The first phase of
Awaab’s Law
came into force for social housing in England in October 2025.

2026: measuring the indoor fungal environment

Researchers are now moving beyond questionnaires and visible mould to analyse the mixture
of fungal material present in indoor air. This does not yet provide a routine clinical test,
but it gives a much more detailed picture of exposure.

What has changed in 2026?

Several new papers have added important pieces to the evidence. They do not overturn the
existing consensus. Instead, they begin to answer questions that older research could not.

1. What fungi are people actually breathing inside UK homes?

The most important new UK exposure study was published in The Lancet Microbe by
Samuel Hemmings and colleagues.

The researchers sampled air in 118 West London households, with repeated
sampling across different seasons. They used passive air samplers, DNA sequencing and
quantitative PCR rather than relying only on visible mould or attempting to grow selected
fungi in culture.

Across 262 indoor and outdoor samples, the researchers detected more than
2,000 fungal genera. Indoor fungal communities were significantly richer,
more diverse and more variable between locations than the communities detected at the
outdoor sampling sites. Indoor communities also showed much stronger seasonal cycling.
:contentReference[oaicite:0]{index=0}

Several medically relevant genera, including Aspergillus,
Penicillium and Wallemia, were enriched indoors. Visible mould was
associated with some of the highest total fungal burdens measured in the study.
:contentReference[oaicite:1]{index=1}

Read the original open-access paper: Hemmings SJ et al. Diversity analysis of indoor and outdoor fungal bioaerosols in UK households
.

Visible mould was not the whole story

One of the most clinically interesting observations involved a home in which no visible mould
was found. A child living there had uncontrolled asthma, confirmed Aspergillus
allergy and repeated hospital admissions.

The total fungal burden in that home was close to the study median, but
Aspergillus was unusually prominent and its estimated absolute abundance was among
the highest in the study. :contentReference[oaicite:2]{index=2}

This single household cannot prove that the exposure caused the child’s hospitalisations.
It does, however, show why visual inspection alone cannot describe the full fungal environment
inside a property.

A home can have a potentially important airborne fungal profile even when no large patch of
mould is visible.

What this study does not tell us

This was principally an environmental exposure study, not a clinical trial designed to prove
that particular fungal measurements caused illness.

It does not establish:

  • a safe or unsafe numerical threshold for indoor fungal exposure;
  • that greater fungal diversity is necessarily harmful;
  • that every home should undergo commercial air testing;
  • that detecting Aspergillus means someone will develop aspergillosis;
  • that one measurement can predict an individual patient’s symptoms.

Its importance is that it establishes a detailed UK baseline and demonstrates methods that
may support better research and surveillance in the future.

2. Long-term exposure and the development of respiratory disease

A second 2026 study examined dampness and mould exposure over approximately 20 years in more
than 8,400 adults participating in the Respiratory Health in Northern Europe
study.

Long-term exposure was associated with the later onset of respiratory symptoms, asthma and
rhinitis. Exposure reported in both the home and workplace appeared more concerning than
exposure in only one setting.

This is important because much of the earlier evidence was based on cross-sectional studies,
which measure housing conditions and health at roughly the same time. Longitudinal research
is better able to establish that exposure occurred before the new health outcome, although it
still cannot remove every possible confounding factor.

Read: Wang J et al. Dampness and mould over 20 years and new onset of respiratory symptoms, asthma and rhinitis
.

3. Damp housing and mental health

The health burden of damp housing is not limited to the lungs. Living with an unresolved
leak, damaged belongings, unpleasant smells, repeated cleaning, disputes over repairs and
fear for a child’s health can be profoundly stressful.

A 2026 analysis published in the American Journal of Epidemiology found an
association between damp housing and psychological distress. The association was stronger
among people who already had a chronic respiratory condition.

This does not establish that inhaled mould directly causes every mental-health effect. Much
of the burden may arise through the combined effects of physical symptoms, housing insecurity,
financial pressure, disrupted sleep, loss of belongings and difficulty obtaining repairs.

Read: Gatto MR et al. The effect of damp housing on psychological distress: does respiratory health matter?
.

4. Flooding and water-damaged buildings

Climate change and more frequent extreme rainfall are increasing interest in the health
consequences of flooded buildings.

A 2026 study in the Journal of Cleaner Production examined new respiratory symptoms
following major flooding. Indoor mould, flood depth, roof condition, ventilation and other
building characteristics emerged as important predictors.

The findings support an established practical principle: after water damage, buildings need
to be dried, assessed and repaired promptly. Simply redecorating a surface while moisture
remains within walls, floors or furnishings may leave the underlying problem unresolved.

Read: Pakdehi M et al. Impacts of major floods on new human respiratory health symptoms in indoor environments
.

5. Can greener and better-insulated homes remain healthy?

Another important 2026 paper approached the problem from building science rather than
medicine.

The open-access review in npj Materials Degradation, part of the Nature Portfolio,
examined the mould susceptibility of bio-based insulation materials used in modern
construction.

Materials made from plant or other biological sources can reduce the environmental impact of
construction. However, because they contain organic material, some can support fungal growth
if they become persistently wet.

The review found that meaningful comparison between products is difficult because laboratory
testing methods vary and do not always reproduce conditions inside real buildings. The authors
called for standardised testing and better long-term evidence from occupied buildings.

Read: Wildman J et al. Mould susceptibility of bio-based insulation materials in modern construction
Energy efficiency and healthy indoor air are not competing goals. Buildings need insulation, moisture control and effective ventilation to be considered together.

What does all of this mean?

The new studies fit together rather than contradicting one another:

  • Long-term population studies show that prolonged exposure is associated
    with new respiratory disease.
  • The UK household study shows that indoor fungal communities can differ
    greatly from outdoor air and from one home to another.
  • Mental-health research shows that the consequences extend beyond physical
    respiratory symptoms.
  • Flood research highlights the importance of rapid drying and building repair.
  • Building-material research shows that moisture resilience must be included
    when homes are insulated or refurbished.

We are therefore moving from a fairly broad conclusion—
damp buildings are associated with poor health—towards more detailed questions:

  • Which fungi and other microbial products are present?
  • What are their sources?
  • How does exposure vary through the year?
  • Which people are most susceptible?
  • What level and duration of exposure are harmful?
  • Which repairs and ventilation interventions produce meaningful health improvements?

Why some people are more vulnerable

Most people inhale fungal spores every day without developing fungal disease. Health effects
depend on the person, the building, the mixture of exposures and the duration of exposure.

Greater caution is appropriate for:

  • babies and children;
  • people with asthma or severe asthma;
  • people sensitised or allergic to fungi;
  • people with ABPA;
  • people with bronchiectasis, COPD or other chronic lung disease;
  • people with CPA or another form of aspergillosis;
  • people whose immune system is significantly weakened;
  • older people and those with reduced mobility.

For people with asthma, fungal sensitisation or ABPA, exposure may trigger allergic airway
inflammation. In someone with damaged lungs, impaired mucus clearance or substantial immune
suppression, the clinical questions may be different and should be discussed with the
treating team.

Can indoor mould cause aspergillosis?

Aspergillus is common in the wider environment as well as indoors. Detecting it in a
home does not prove that it caused a person’s aspergillosis, and it is usually impossible to
trace an individual infection or allergic response to one particular building.

However, avoiding persistent and unnecessary high exposure is sensible, particularly for
people with fungal allergy, ABPA, damaged lungs or significant immune suppression.

Our guide to reducing exposure to mould and Aspergillus at home
explains practical steps without suggesting that a home can or should be made completely
free of fungal spores.

Should you buy a home mould test?

Routine commercial testing is not normally the first or most useful response to visible damp
or mould.

There are currently no universally accepted health-based numerical limits for total indoor
fungal bioaerosols. A sample may also vary according to the room, season, weather, sampling
method and activity in the home.

A result showing that fungi are present does not by itself establish:

  • that the level is dangerous;
  • that the fungi caused a particular illness;
  • where the moisture is entering the building;
  • what repair is required.

Where damp, leaks, condensation or mould are already apparent, the priority is usually a
competent inspection of the building and correction of the moisture source.

What to do if your home is damp or mouldy

  1. Record the problem. Photograph visible mould, staining, condensation, leaks
    and damaged possessions. Record dates, affected rooms and previous reports.
  2. Report it in writing. Tenants should notify their landlord or housing
    provider and keep copies of messages and repair reports.
  3. Ask for the underlying cause to be investigated. Possible causes include
    plumbing or roof leaks, penetrating or rising damp, inadequate insulation, cold bridges,
    defective extraction and insufficient ventilation.
  4. Explain relevant health vulnerabilities. State clearly when a household
    member has asthma, chronic lung disease, fungal allergy, aspergillosis, immune suppression
    or another condition that may increase risk.
  5. Reduce moisture where reasonably possible. Use working extractor fans,
    ventilate after bathing or cooking, avoid blocking air vents and dry wet materials promptly.
  6. Do not accept repeated surface treatment as a permanent repair. Cleaning or
    painting may remove visible growth temporarily but will not solve an ongoing moisture defect.

Residents should not be blamed automatically for damp and mould. Everyday activities generate
water vapour, but a healthy building should be capable of managing normal moisture through an
appropriate combination of heating, insulation, extraction and ventilation.

Cleaning mould safely

A small, isolated area of surface mould may sometimes be cleaned after the moisture source has
been corrected. Larger areas, recurrent mould, sewage-contaminated water damage or mould within
porous building materials may require professional assessment.

People with severe asthma, significant fungal allergy, aspergillosis or immune suppression
should avoid carrying out extensive mould removal themselves, because cleaning can release
spores and fragments into the air.

More practical guidance is available in our Housing & Environment Hub
.

When to seek medical advice

Contact your healthcare team when:

  • asthma or breathlessness has become more difficult to control;
  • you are waking at night because of cough, wheeze or chest tightness;
  • you are needing reliever medication more frequently;
  • you have recurrent chest infections or worsening sputum production;
  • symptoms repeatedly improve away from the building and return after coming home;
  • you have aspergillosis, fungal allergy or immune suppression and substantial mould exposure;
  • the housing problem is causing serious anxiety, poor sleep or psychological distress.

Severe breathlessness, blue or grey lips, confusion, collapse, marked difficulty speaking or
a rapidly deteriorating asthma attack requires urgent medical help.

What remains uncertain?

Important gaps remain despite the strength of the overall evidence.

  • There is no single health-based threshold that defines a safe total indoor fungal count.
  • No one test captures all spores, fragments, allergens, microbial compounds and co-exposures.
  • The health importance of a fungal genus depends on species, quantity and individual susceptibility.
  • Associations observed in populations cannot prove the cause of every individual illness.
  • More high-quality intervention studies are needed to establish which repairs deliver the greatest health benefit.

A Cochrane review of remediation in damp and mould-damaged buildings found some evidence that repairs can reduce respiratory symptoms, but also highlighted the limited number and variable quality of intervention studies.

The benchmark conclusion in 2026

The current scientific position can be summarised carefully:

Persistent dampness and mould in homes and workplaces are preventable environmental health
hazards. They are associated with asthma, respiratory symptoms, infections, allergic disease
and psychological distress, with greater concern for people who already have respiratory or
immune vulnerability.

The most important practical intervention remains the same: identify and correct the source of
moisture, dry the building and remove damaged or mould-contaminated material appropriately.

What has changed is our ability to examine exposure. New DNA-based studies show that indoor
fungal communities are complex, seasonal and highly variable between homes. This may eventually
allow better exposure standards and more targeted interventions, but the science is not yet at
the point where a commercial air sample can reliably predict an individual person’s health risk.

Further information and support

Selected evidence

  1. Hemmings SJ, Varaden D, Barnes J, et al. Diversity analysis of indoor and outdoor
    fungal bioaerosols in UK households: a prospective, observational, longitudinal study.
    Lancet Microbe. 2026;7:101379.
    View the paper.
  2. World Health Organization. WHO Guidelines for Indoor Air Quality: Dampness and
    Mould
    . WHO Regional Office for Europe; 2009.
    View the guideline.
  3. Mendell MJ, Mirer AG, Cheung K, Tong M, Douwes J. Respiratory and allergic health
    effects of dampness, mould, and dampness-related agents: a review of the epidemiologic
    evidence. Environmental Health Perspectives. 2011;119:748–756.
    PubMed.
  4. Varga MK, et al. Childhood asthma and mould in homes: a meta-analysis.
    Allergy. 2025.
    PubMed.
  5. Groot J, et al. Residential mould and dampness and the risk of respiratory tract
    infections and respiratory symptoms in children: a systematic review and meta-analysis.
    PubMed.
  6. Wang J, Holm M, Dahlman-Höglund A, Janson C, et al. Dampness and mould over 20 years
    and new onset of respiratory symptoms, asthma and rhinitis.
    Journal of Hazardous Materials. 2026.
    View the paper.
  7. Gatto MR, Li A, Martino E, Bentley R. The effect of damp housing on psychological
    distress: does respiratory health matter?
    American Journal of Epidemiology. 2026;195:1292–1299.
    PubMed.
  8. Pakdehi M, Ahmadisharaf E, Suliman AA, Abdelrazig Y. Impacts of major floods on new
    human respiratory health symptoms in indoor environments.
    Journal of Cleaner Production. 2026;557:148247.
    View the paper.
  9. Wildman J, Shea A, Cascione V, et al. Mould susceptibility of bio-based insulation
    materials in modern construction. npj Materials Degradation. 2026;10:29.
    View the open-access review.
  10. Sauni R, Verbeek JH, Uitti J, Jauhiainen M, Kreiss K, Sigsgaard T. Remediating
    buildings damaged by dampness and mould for preventing or reducing respiratory tract
    symptoms, infections and asthma. Cochrane Database of Systematic Reviews. 2015.
    View the review.
Medical note: This page provides general information and cannot determine
whether a particular home caused an individual illness. Medical symptoms should be assessed
by an appropriate healthcare professional, while the building itself should be assessed by
someone competent to investigate moisture, ventilation and structural defects.

Person overlooking a smoky landscape affected by wildfire, illustrating the importance of protecting lung health and reducing smoke exposure for people with aspergillosis, asthma, bronchiectasis and COPD.

Wildfire smoke and aspergillosis: protecting your lungs when air quality falls

Person overlooking a smoky landscape affected by wildfire, illustrating the importance of protecting lung health and reducing smoke exposure for people with aspergillosis, asthma, bronchiectasis and COPD.
Wildfire smoke can travel hundreds of miles and temporarily reduce air quality. People with aspergillosis and other chronic lung conditions should monitor air quality, reduce smoke exposure and continue their prescribed treatment.

Wildfires in parts of the UK and Europe can produce smoke that travels considerable distances. Even when a fire is many miles away, fine particles carried in the air may temporarily reduce local air quality.

People with aspergillosis, asthma, bronchiectasis, COPD or another chronic lung condition may be more sensitive to wildfire smoke. Smoke can irritate the airways and cause coughing, wheezing, chest tightness, breathlessness, sore eyes or a sore throat. It can also aggravate an existing respiratory condition.

Check the air quality where you live. UK residents can use the official Defra UK Air website. International websites such as IQAir can also provide useful local maps, forecasts and measurements.

What should people with lung conditions do?

UK health advice recommends reducing exposure to smoke and air pollution, particularly if you develop symptoms.

  • Reduce strenuous outdoor activity. Exercise causes you to breathe more deeply and may increase the amount of smoke particles reaching your lungs.
  • Stay indoors when smoke is affecting your area and keep doors and windows closed while the outdoor air quality is poor.
  • Ventilate when conditions improve. Open windows when the smoke has cleared and outdoor air quality is better, particularly if the building is becoming hot.
  • Take your usual medication as prescribed. Do not alter antifungal treatment, inhalers, steroids or other medicines unless advised by your healthcare team.
  • Keep your reliever inhaler with you if one has been prescribed.
  • Follow your asthma, COPD, bronchiectasis or respiratory action plan if you have one.
  • Avoid adding more particles indoors. During a smoke episode, avoid smoking, wood-burning stoves, candles and other activities that create smoke.
  • Keep cool and hydrated. Wildfires often occur during hot weather, which can place additional strain on people with heart, lung, kidney or other long-term conditions.

Do masks help?

A well-fitting particulate respirator such as an FFP2 or FFP3 mask may reduce the amount of fine particulate matter inhaled while outdoors. Loose-fitting surgical or fabric masks provide much less protection against fine smoke particles.

However, some people with significant lung disease may find tight-fitting masks uncomfortable or may become more breathless while wearing one. A mask should not be used as a reason to remain outdoors in heavy smoke. Reducing exposure remains the priority.

Does wildfire smoke increase Aspergillus infection?

Wildfire smoke is primarily a mixture of gases and very small particles produced by burning vegetation and other materials. Its immediate health effect is irritation and inflammation of the lungs and airways.

Smoke exposure does not necessarily mean that Aspergillus is growing in the lungs or that aspergillosis is worsening. However, people whose lungs are already damaged or inflamed may notice increased coughing, wheezing, mucus production or breathlessness.

Symptoms caused by smoke can resemble a respiratory flare-up. Contact your healthcare team if symptoms are new, unusually severe, persist after the air quality has improved, or are not controlled by your normal treatment plan.

When should you seek medical help?

Contact your GP, respiratory team or NHS 111 if:

  • you develop new or worsening breathlessness, wheezing or chest tightness;
  • you need your reliever inhaler more often than usual;
  • your symptoms are not responding to your agreed treatment plan;
  • your symptoms persist after the smoke has cleared; or
  • you are concerned about a change in your condition.

Call 999 for severe breathing difficulty. This includes rapidly worsening breathlessness, being unable to speak normally, becoming confused or drowsy, developing blue or grey lips or skin, or an asthma attack that is not improving after using your reliever inhaler as directed.

Understanding air-quality alerts

The UK Daily Air Quality Index runs from 1 to 10:

  • Low, 1–3: most people can continue normal outdoor activity.
  • Moderate, 4–6: people with lung or heart conditions who develop symptoms should reduce strenuous outdoor activity.
  • High, 7–9: people with lung conditions should reduce strenuous outdoor exertion, particularly if symptomatic.
  • Very high, 10: people with lung or heart conditions and older adults should avoid strenuous physical activity.

People vary considerably in their sensitivity. Some people with severe asthma, bronchiectasis or aspergillosis may experience symptoms even when the overall air-quality rating is described as low or moderate. Your symptoms and personal respiratory action plan remain important.

Useful sources

This information is intended as general guidance and does not replace advice from your own healthcare team.


Couple walking together along a winding coastal path symbolising the emotional journey of living with chronic illness, including hope, setbacks, recovery and ongoing adaptation.

Learning to Live with Chronic Illness: Is It Really Like Grieving?

Couple walking together along a winding coastal path symbolising the emotional journey of living with chronic illness, including hope, setbacks, recovery and ongoing adaptation.
Living with a chronic illness is rarely a straight path. Many people experience repeated cycles of adjustment as their condition changes over time. This image represents the shared journey of patients and families, moving forward together through hope, setbacks and recovery.

“How do you accept having a chronic illness? Is it a grieving process?”

It is one of the most thoughtful questions anyone living with a long-term health condition can ask.

Whether you have aspergillosis, bronchiectasis, severe asthma, COPD or another chronic illness, many people describe life as having two chapters: before illness and after illness.

Most of us grow up assuming our health will simply be there in the background. We make plans, book holidays, think about retirement, imagine spending time with grandchildren, travelling or enjoying hobbies. We rarely question whether our bodies will allow us to do these things.

Then, sometimes quite suddenly, life changes.

Perhaps the diagnosis follows weeks of investigations. Perhaps it comes after years of unexplained symptoms, repeated infections or unsuccessful treatments. Whatever the route, many people describe the feeling that the future they expected has quietly disappeared.

The physical symptoms may be obvious.

The emotional changes are often much harder to see.

That is why so many people describe living with chronic illness as a form of grief.

Grieving for the life you expected

When we hear the word grief, we usually think about losing someone we love.

However, grief can follow many different kinds of loss. A chronic illness may bring several losses, not necessarily all at once, but gradually over time.

You may grieve:

  • the health you once took for granted
  • your confidence in your body
  • your independence or spontaneity
  • work or career opportunities
  • financial security
  • hobbies and activities that have become more difficult
  • changes in relationships or family roles
  • the future you had imagined.

Perhaps you can no longer walk as far as you once did. Perhaps you worry about booking a holiday because you do not know how you will feel when the time comes. Perhaps you miss being the person everyone relied upon.

You may also miss the freedom of doing something without first considering your symptoms, medication, energy levels or access to healthcare.

These are genuine losses, even when nobody else can see them.

It is therefore entirely understandable that they may be accompanied by sadness, frustration, anger or fear.

The hidden or “side” griefs

One patient described something that many people immediately recognised: the “side griefs”.

These are the numerous, seemingly small losses that accompany chronic illness. Individually, they may not appear life-changing. Together, they can gradually reshape everyday life.

Perhaps you stop gardening because your breathing or energy will not allow it.

Perhaps you can no longer play with your grandchildren in the same way.

Perhaps you avoid crowded places because you are concerned about infection.

Perhaps you have become the person who always has to ask, “How far is the walk?” or “Will there be somewhere to sit?”

Perhaps an invitation that once brought excitement now brings several calculations: How will I travel? Will I have enough energy? What happens if I become unwell? Can I cancel at short notice?

None of these changes may appear dramatic to other people. Together, however, they can change how you see yourself and the life you live.

“Shouldn’t I be over this by now?”

Many people feel guilty about continuing to struggle emotionally after their diagnosis.

Friends and relatives may say:

“At least it is being treated.”

“You look well.”

“Try to stay positive.”

These comments are usually intended to be reassuring. However, living with a chronic illness is not simply about receiving treatment and then carrying on as before. It frequently requires further practical and emotional adjustment.

Some days that adjustment feels manageable. Other days it feels exhausting.

There is no correct timetable for coming to terms with a life-changing diagnosis.

Is there really a grieving process?

You may have heard of the “five stages of grief”: denial, anger, bargaining, depression and acceptance.

These ideas have helped many people put words around difficult emotions, but real life is rarely so orderly. People do not necessarily move neatly from one stage to the next, and not everyone experiences all of them.

You might feel angry when you are first diagnosed and then optimistic when treatment begins. You may feel settled for several months, only to become frightened again before a scan or clinic appointment.

A flare-up, hospital admission or change in treatment may bring back feelings you thought you had already dealt with.

This does not mean that you are going backwards.

It means you are responding to a changing situation.

Research into psychological adjustment to chronic disease suggests that people differ greatly in how they respond and that adjustment can vary across the course of an illness. There is no single emotional pathway that everyone must follow.

The emotional rollercoaster

Many people imagine that accepting a diagnosis is something that happens once.

Patients often describe something very different.

Living with chronic illness can feel like an emotional rollercoaster.

Good clinic appointments may be followed by disappointing ones.

One blood test brings relief. The next raises new questions.

A scan may show improvement, only for a new symptom to appear.

A treatment begins to work, but later causes side effects or needs to be changed.

One day you almost forget that you are ill. The next day, getting dressed may feel like hard work.

Hope and disappointment.

Confidence and uncertainty.

Good days and bad days.

This continual movement can be exhausting. Just as you begin to feel that life is becoming predictable again, something changes.

Many people say that they are emotionally tired as well as physically tired.

Good days and bad days

Good and bad days can affect how you understand your illness.

On a good day, you may wonder whether you have been too cautious or whether things are finally returning to normal.

On a bad day, you may fear that your illness is getting worse or that the improvement was never real.

Both reactions are understandable, but one day rarely tells the whole story.

Over time, many people learn to look for patterns over weeks or months rather than judging their health by one particularly good or difficult day.

A bad day does not necessarily mean that your condition is deteriorating.

A good day does not mean that the illness has disappeared.

One of the hardest skills is learning to enjoy a good day without spending it worrying about the next bad one. Another is remembering during a difficult day that how you feel today may not be how you feel tomorrow.

You do not adapt once

Perhaps the biggest misconception about chronic illness is that acceptance is a single event.

In reality, most people do not adapt once.

They adapt hundreds of times.

You adapt to the diagnosis.

Then to the first treatment.

Then to side effects.

Then to improvement.

Then to a setback.

You adapt to hospital appointments, new symptoms, reassuring results and worrying results.

You adapt to holidays that have to be cancelled and holidays that go better than expected.

You adapt to asking for help when you were previously independent and to saying no when you would once have said yes.

Every change asks you to adjust again.

This does not mean that you have failed to accept your illness. It reflects the reality of living with a condition that can fluctuate and change over time.

Acceptance is dynamic

Perhaps we should stop thinking of acceptance as something we either achieve or fail to achieve.

Acceptance is dynamic.

It changes as your illness changes, as treatments change and as life itself changes around you.

Every new situation may require another adjustment.

Acceptance is not a finish line. It is an ongoing process of recognising where you are now, adjusting your expectations and protecting the things that remain important to you.

Acceptance does not mean giving up.

It does not mean liking what has happened, pretending everything is fine or abandoning hope for better treatment.

It means recognising the reality of today without spending all your energy fighting the fact that the illness exists.

Many people describe a gradual shift. Instead of repeatedly asking:

“Why has this happened to me?”

they begin to ask:

“Given where I am today, how can I live as well as possible?”

The first question is entirely understandable, but it may never have a satisfying answer. The second may create choices, even when those choices are limited.

Not every day has to be positive

People living with chronic illness are often encouraged to “stay positive”.

The intention is usually kind. Sometimes, however, it can feel like another burden.

The reality is that some days are simply difficult.

You do not have to find a positive lesson in every setback.

You do not have to feel grateful every day.

You do not have to pretend that losing something important does not hurt.

Sometimes the healthiest response is simply to acknowledge:

“Today is hard.”

Tomorrow may be different.

When illness affects the whole family

Chronic illness rarely affects only the person who has been diagnosed.

Partners, children, relatives, friends and carers may also live with uncertainty, disrupted plans, additional responsibilities and concerns about the future.

A partner may not know whether to encourage activity or suggest rest. A relative may struggle to understand why someone can manage an outing one day but has to cancel plans the next. A carer may be carrying practical responsibilities while also trying to manage their own emotions.

Because symptoms fluctuate, family members may sometimes misread what is happening.

On a good day, they may assume that the illness is improving permanently. On a bad day, they may wonder why everything has suddenly changed again.

The person who is ill may then feel disbelieved, pressured or guilty. The family member may feel rejected, confused or unappreciated.

Nobody necessarily intends to hurt anyone, but frustration on both sides can make an already difficult situation feel worse.

Patients may feel guilty about cancelling plans, needing help or placing additional demands on those around them. Carers may feel guilty for becoming tired, impatient or resentful.

These feelings do not mean that anyone cares less. They usually mean that everyone is trying to adapt to a situation they did not choose.

Open communication can help. It may be useful to explain that symptoms fluctuate, that a good day does not mean the illness has disappeared, and that a cancelled plan is not a rejection.

It is equally important for carers and relatives to be honest about their own limits and to have time, support and interests that do not revolve entirely around illness.

Sometimes the most useful conversation is not about solving the problem. It is simply acknowledging:

“This is difficult for both of us, and neither of us is to blame.”

Both the person living with illness and the people supporting them may have to adapt hundreds of times. Doing that together requires patience, honesty and permission for everyone involved to have difficult days.

Families and friends supporting someone with chronic pulmonary aspergillosis may also find our guide to CPA for family and friends helpful.

Living with uncertainty

One of the hardest parts of chronic illness is often uncertainty.

You may not know how well a treatment will work, whether symptoms will improve or how much energy you will have tomorrow.

This unpredictability can make planning difficult. It may also make you feel that you cannot entirely trust your body.

Some people respond by constantly watching for symptoms or imagining everything that might go wrong. This is understandable, particularly after frightening experiences, but remaining permanently on alert can itself become exhausting.

Acceptance does not remove uncertainty. It can, however, help you concentrate more of your attention on what is happening today rather than trying to solve every possible version of the future.

The NHS guide to coping with change and uncertainty offers practical suggestions for focusing on the short term, recognising what is working and finding a new rhythm.

What helps people adapt?

There is no single method that works for everybody. However, research and the experiences of people living with chronic illness suggest that several things can help.

Understanding your condition

Reliable information can reduce some of the fear created by uncertainty. Understanding your condition, treatment and warning signs can help you feel more prepared and involved in decisions about your care.

At the same time, it is possible to become overwhelmed by searching for information. It may help to use a small number of trusted sources and discuss important questions with your healthcare team.

Managing energy rather than fighting it

Fatigue is not simply ordinary tiredness. It can affect concentration, confidence, relationships and emotional wellbeing as well as physical activity.

Learning to pace activity, prioritise important tasks and allow time for recovery is not laziness or surrender. It is a practical response to limited energy.

Our guide to managing fatigue and energy in aspergillosis and allergic fungal lung disease explains pacing, the “boom-and-bust” cycle and ways to use limited energy more effectively.

Talking honestly

Family and friends may want to help but may not understand what you need. They may see you on a relatively good day and assume that your illness has improved.

It can help to explain that symptoms fluctuate and that cancelling a plan does not mean you no longer care about the people involved.

You do not have to tell everyone everything. However, being honest with a few trusted people can reduce the effort involved in constantly pretending to be well.

Connecting with people who understand

Support from other patients can provide something that even loving relatives and skilled healthcare professionals may not always be able to offer: recognition from someone who has experienced something similar.

People may exchange practical ideas, but sometimes the most important benefit is simply hearing:

“I understand. I have felt that too.”

Our aspergillosis support groups and meetings provide welcoming online spaces for patients, carers and supporters. You can also explore the wider aspergillosis community and support hub.

Making room for difficult emotions

Trying to suppress every frightening, angry or unhappy thought can require enormous effort.

Approaches such as mindfulness and Acceptance and Commitment Therapy, usually shortened to ACT, do not ask people to pretend that difficult feelings are unimportant. Instead, they aim to help people make room for those feelings while continuing to take actions connected with what matters to them.

The aim is not to eliminate all distress. It is to reduce the extent to which distress controls every decision.

Our article on managing the stress of living with chronic disease explores grounding, mindfulness, breathwork and other ways of responding to prolonged stress.

Setting goals that belong to your life now

Goals can restore a sense of direction and control, but they may need to change.

A goal does not have to be dramatic. It might be:

  • taking a short walk
  • meeting a friend
  • returning to a hobby in a modified form
  • attending an important family occasion
  • preparing one meal
  • asking for help before reaching exhaustion.

Changing a goal is not necessarily failure. Sometimes it is how we preserve the part of the goal that matters most.

You are more than your diagnosis

One danger of chronic illness is that it can gradually take over your identity.

Medical appointments, symptoms, prescriptions and test results may begin to dominate everyday conversation. You may find yourself thinking about your life mainly in terms of what your body can no longer do.

But you are not simply “an aspergillosis patient”.

You may also be a parent, partner, grandparent, friend, musician, gardener, engineer, teacher, artist or volunteer.

Illness may change how you fulfil those roles. It does not erase them.

It can help to ask:

“What matters to me, and is there another way I can still be part of it?”

You may no longer be able to host a large family gathering, but perhaps you can spend quieter time with one or two people. You may no longer manage a full day in the garden, but you may still be able to grow something in a container near the house.

Adaptation is not always about doing less. Often, it is about protecting what matters most.

Where people find strength

Although the journey is different for everyone, many people eventually discover something that helps them continue moving forward.

For some, it is family or friendship.

For others, it is faith.

Some find strength in nature, creativity, humour, community, personal values or helping other people.

One patient shared these words with us:

“I have to constantly remind myself that God is sovereign and in all things He is working for good to bring me to a greater understanding of who He is.”

Not everyone shares the same beliefs, but many people describe finding comfort in something that feels larger than the illness itself. That source of strength is deeply personal, and there is no single right answer.

Hope changes too

When people are first diagnosed, hope often means hoping for a cure or a complete return to their previous life.

Over time, hope may take on different forms.

Hope may mean:

  • having more good days than bad ones
  • finding a treatment with fewer side effects
  • walking a little further than last month
  • reducing the need for steroid treatment
  • taking a holiday
  • seeing grandchildren grow up
  • feeling useful and connected
  • discovering that life still contains pleasure and meaning.

This is not necessarily a smaller or weaker form of hope.

It is hope that has adapted to reality while continuing to look forward.

When additional help may be needed

Sadness, frustration, anger and fear are understandable responses to chronic illness. However, sometimes emotional distress becomes persistent or begins to affect every part of life.

Consider speaking to your GP or healthcare team if you are:

  • feeling low or hopeless most of the time
  • experiencing frequent panic or overwhelming anxiety
  • withdrawing from everyone around you
  • unable to sleep because of worry
  • losing interest in nearly everything you previously valued
  • finding that distress is making it difficult to manage medication, food or basic daily care.

Seeking psychological support does not mean that your physical symptoms are “all in your head”. Chronic physical illness places genuine demands on emotional wellbeing, and receiving help with those demands is part of caring for the whole person.

The NHS has practical guidance on looking after your mental health when living with physical illness. Its Every Mind Matters service also provides advice about stress, anxiety, low mood and sleep.

You are not alone

If you are finding it difficult to accept a chronic illness, you are in very good company.

Almost everyone living with a long-term condition experiences periods of sadness, frustration, fear or grief.

These feelings do not mean you are weak.

They do not mean you are failing.

They mean you are adapting to one of life’s greatest challenges.

Not once, but over and over again.

You may adapt hundreds of times during your journey:

To good news.

To bad news.

To better days.

To worse days.

To new medication.

To unexpected side effects.

To a reassuring scan.

To a worrying blood result.

To holidays that happen.

To holidays that have to be cancelled.

To the loss of something you valued.

To the discovery of something new that brings you joy.

Acceptance is not a finish line.

It is a lifelong process of adapting to change while holding on to the things that matter most.

Life may not be the one you planned.

But it can still be a life filled with love, purpose, hope and moments of genuine happiness.


Further support

Living with chronic illness can sometimes feel overwhelming, but you do not have to face it alone.

You may find it helpful to talk to:

  • your GP
  • your respiratory or specialist team
  • a trusted friend or relative
  • a counsellor, psychologist or NHS Talking Therapies service
  • other people living with a similar condition.

For aspergillosis-specific support, visit our support groups and meetings page.

References and further reading

  • Stanton AL, Revenson TA, Tennen H. Health psychology: psychological adjustment to chronic disease. Annual Review of Psychology. 2007;58:565–592. View on PubMed.
  • Bonanno GA, Westphal M, Mancini AD. Resilience to loss and potential trauma. Annual Review of Clinical Psychology. 2011;7:511–535. View on PubMed.
  • Graham CD, Gouick J, Krahé C, Gillanders D. A systematic review of the use of Acceptance and Commitment Therapy in chronic disease and long-term conditions. Clinical Psychology Review. 2016;46:46–58. View on PubMed.
  • Herbert MS, Dochat C, Wooldridge JS, et al. Technology-supported Acceptance and Commitment Therapy for chronic health conditions: a systematic review and meta-analysis. Behaviour Research and Therapy. 2022;148:103995. View on PubMed.

This article provides general information and emotional support. It is not a substitute for individual medical or psychological advice. Please speak to your GP, specialist team or another qualified healthcare professional about your own circumstances.


Aspergillosis research update infographic summarising July 2026 studies on invasive aspergillosis, isavuconazole, macrophages and tuberculosis.

Aspergillosis Research Update: ICU Infections, Immune Defences and Antifungal Treatment

Aspergillosis research update infographic summarising July 2026 studies on invasive aspergillosis, isavuconazole, macrophages and tuberculosis.
This month's research highlights a major international review of invasive aspergillosis in intensive care, encouraging real-world data on isavuconazole, and two studies exploring how macrophages may influence the body's defence against Aspergillus infection.

Published: July 2026

Medical research into aspergillosis continues to advance rapidly, with new studies appearing almost every week. Some confirm what doctors already suspected, while others introduce new ideas about how the body fights fungal infections or how treatment might improve in the future.

This week’s research includes a major international review of invasive aspergillosis in intensive care, encouraging real-world results for the antifungal drug isavuconazole, and two laboratory studies suggesting that specialised immune cells called macrophages may play an even greater role in protecting the lungs than previously appreciated.

None of these studies changes current treatment recommendations immediately. Together, however, they highlight an important direction in aspergillosis research: understanding not only how to kill the fungus, but also how to strengthen the body’s own immune defences.


A major international review confirms the burden of invasive aspergillosis in intensive care

A systematic review and meta-analysis combined results from 56 observational studies involving 15,385 intensive care patients. Among these patients, 2,381 cases of invasive pulmonary aspergillosis, or IPA, were identified.

The researchers estimated that IPA occurred in approximately 11.9% of the critically ill patients included in the studies. The estimated incidence increased to 15% among patients receiving mechanical ventilation.

Mortality among patients diagnosed with IPA was high:

  • 59.6% overall mortality
  • 61.9% mortality among mechanically ventilated patients

Factors associated with an increased risk of developing IPA included:

  • immunosuppression;
  • blood cancers and other malignancies;
  • corticosteroid use before admission to intensive care;
  • chronic lung, kidney, liver or heart disease;
  • mechanical ventilation;
  • vasopressor treatment;
  • and renal replacement therapy.

What does this mean?

This study reinforces that invasive aspergillosis remains a serious complication in selected critically ill patients.

However, the results should not be interpreted as meaning that approximately one in eight people admitted to intensive care will develop aspergillosis. The authors state that the evidence predominantly reflects COVID-19-associated pulmonary aspergillosis, commonly known as CAPA.

Many of the identified risk factors, such as mechanical ventilation, vasopressor treatment and renal replacement therapy, are also signs that a patient is already extremely unwell. The study therefore identifies associations but cannot prove that these treatments independently cause aspergillosis.

The authors conclude that targeted screening and tailored antifungal strategies in high-risk patients deserve prospective evaluation. They do not claim that universal screening or preventive antifungal treatment has already been shown to improve survival.

Read the paper record on PubMed


Real-world evidence continues to support isavuconazole

Another study examined how well isavuconazole performs in routine clinical practice among people with blood cancers who develop serious invasive mould infections.

The retrospective study included 84 adults treated at two hospitals in China between 2022 and 2025:

  • 62 had invasive aspergillosis;
  • 14 had mucormycosis;
  • 8 had mixed mould infections.

The main measure of success was assessed after six weeks. To count as successful treatment, the patient had to survive, show clinical or radiological improvement and avoid stopping treatment because of failure or toxicity.

The overall six-week treatment success rate was 59.5%. Among patients with aspergillosis, treatment success was higher, at 69.4%.

Only four patients experienced recorded drug-related adverse effects, and one stopped treatment because of vomiting.

What does this mean?

These findings are reassuring because they reflect routine clinical practice rather than the more controlled circumstances of a clinical trial.

The study found that patients receiving isavuconazole alone appeared to have better outcomes than those receiving combination antifungal treatment. However, this result must be interpreted cautiously.

Doctors commonly reserve combination therapy for patients who are more severely ill, have failed previous treatment, have mixed infections or are suspected of having resistant disease. The poorer outcomes in the combination-treatment group may therefore reflect the severity of the patients’ infections rather than harm caused by combining antifungal medicines.

This is known as confounding by indication. Because the patients were not randomly assigned to treatment, the study cannot establish that monotherapy is superior to combination treatment.

Overall, the study adds confidence that isavuconazole can be an effective and generally well-tolerated treatment for invasive aspergillosis in patients with haematological malignancies. It does not show that isavuconazole is better than other antifungal medicines, and it does not apply directly to chronic pulmonary aspergillosis, ABPA or Aspergillus bronchitis.

Read the paper record on PubMed


Could strengthening lung macrophages help prevent invasive aspergillosis?

Perhaps the most scientifically intriguing study this week did not test a new antifungal drug.

Instead, researchers investigated whether they could improve the ability of the lung’s own immune cells to eliminate Aspergillus fumigatus before infection became established.

The study focused on alveolar macrophages. These specialised immune cells live inside the air sacs of the lungs and are among the first cells to encounter inhaled Aspergillus spores.

Using a stem-cell transplant mouse model and an unusually low dose of Aspergillus spores intended to resemble everyday exposure, the researchers found that alveolar macrophages played a crucial role in protecting against invasive aspergillosis during the earliest stages of infection.

The researchers then tested whether macrophage function could be improved using macrophage colony-stimulating factor, or M-CSF.

M-CSF treatment:

  • improved macrophage migration;
  • enhanced phagolysosomal function;
  • increased fungal killing;
  • preserved lung tissue;
  • reduced inflammatory cytokines;
  • and protected mice against lethal invasive aspergillosis.

The researchers also tested primary human alveolar macrophages and found that M-CSF improved several of the same antifungal functions.

Importantly, the protective effect disappeared when alveolar macrophages were removed. This provides strong experimental evidence that the macrophages themselves were responsible for much of the benefit.

What does this mean?

This research suggests that tissue-resident macrophages may play an especially important role during the first hours after Aspergillus spores reach the lungs.

It also supports the wider idea of host-directed therapy: treatments designed to strengthen the patient’s immune response rather than attacking the fungus directly.

However, this study was carried out mainly in mice and has been published as a preprint. It has not yet completed formal peer review.

M-CSF is therefore not an established treatment for aspergillosis. Researchers would need to establish appropriate dosing, safety and effectiveness in people, particularly because stimulating immune activity after stem-cell transplantation could potentially affect inflammation, graft-versus-host disease and other immune processes.

Read the bioRxiv preprint


Tuberculosis may affect immune defences as well as damaging the lungs

People who have previously had pulmonary tuberculosis are at increased risk of developing chronic pulmonary aspergillosis, or CPA.

The usual explanation is structural lung damage. Tuberculosis may leave behind cavities, scarring, bronchiectasis and damaged airways, creating an environment in which Aspergillus can persist.

A new laboratory study suggests that there may also be an immunological component.

The researchers studied a mycobacterial cell-wall molecule called lipoarabinomannan, or LAM. This molecule is known to interfere with some of the cellular pathways used by macrophages to respond to infection.

Bone-marrow-derived macrophages were exposed to two forms of LAM and then challenged with swollen Aspergillus fumigatus conidia.

Exposure to LAM:

  • increased macrophage death;
  • increased inflammatory cytokine release, particularly IL-1β;
  • and reduced the ability of macrophages to kill Aspergillus conidia during the first six hours of infection.

The reduction in fungal killing was demonstrated using both colony-counting methods and time-lapse fluorescence microscopy.

What does this mean?

This study provides a plausible biological mechanism through which mycobacterial infection might interfere with early antifungal immune responses.

It does not, however, prove that this mechanism causes CPA after tuberculosis.

The experiments were conducted in laboratory-grown macrophages. They do not show that LAM remains present in the lungs for months or years after tuberculosis, nor that macrophages from people with previous tuberculosis behave in the same way.

The findings therefore do not replace the established structural explanation linking tuberculosis and CPA. Instead, they raise the possibility that lung damage and altered local immunity may work together.

Read the paper record on PubMed


A common theme emerges: macrophages matter

Although these studies examined different questions, two independent research groups reached complementary conclusions.

One study found that strengthening macrophage activity improved fungal killing and survival. The other found that disrupting macrophage activity reduced fungal killing.

Together, they support an emerging view that alveolar macrophages may be central to determining whether inhaled Aspergillus spores are cleared rapidly or allowed to develop into disease.

This does not reduce the importance of neutrophils, antifungal medicines or structural lung damage. Instead, it adds a more detailed understanding of what may happen during the earliest stages of fungal exposure.

Future advances in aspergillosis treatment may therefore involve both:

  • better drugs that attack Aspergillus directly;
  • and treatments that help the immune system respond more effectively.

What does this mean for people living with aspergillosis?

For most patients currently receiving treatment, these studies do not change day-to-day management.

Antifungal medicines remain the foundation of treatment for invasive and chronic Aspergillus infection. Patients should continue following the advice of their respiratory, infectious-diseases or specialist aspergillosis team.

These studies nevertheless provide encouraging evidence that aspergillosis research is progressing across several fronts:

  • improving recognition of invasive aspergillosis in intensive care;
  • evaluating how existing antifungal treatments perform in routine practice;
  • understanding why some people are more vulnerable to Aspergillus than others;
  • and exploring whether the immune system itself could become a future treatment target.

Progress is often gradual, and laboratory findings do not always lead to successful treatments. However, each study adds another piece to the puzzle and helps researchers move towards more effective and more personalised approaches to aspergillosis.


References

  1. Zhou Z, Luo B, Zhang X, et al. Incidence, mortality and risk factors of invasive pulmonary aspergillosis in critically ill patients during the COVID-19 era: a global systematic review and meta-analysis. Annals of Clinical Microbiology and Antimicrobials. Published 10 July 2026. PubMed. DOI.
  2. Zhang J, Xu M, Mao J, et al. Isavuconazole for invasive mold disease in patients with hematological malignancies: a multicenter real-world study from China on efficacy, safety, and competing risks. Antimicrobial Agents and Chemotherapy. Published 6 July 2026. PubMed. DOI.
  3. Sheta D, Mokhtari Z, Strobel M, et al. M-CSF-stimulated alveolar macrophages safeguard from invasive aspergillosis. bioRxiv. Preprint published 9 July 2026. DOI and preprint.
  4. Gonzales-Huerta LE, Williams TJ, Aljohani R, et al. Mycobacterial lipoarabinomannan negatively interferes with macrophage responses to Aspergillus fumigatus in vitro. PLOS ONE. 2026;21(7):e0351935. PubMed. DOI.

This article summarises newly published research for patients and non-specialist readers. It does not replace individual medical advice from a qualified healthcare professional.


Removing mould from a front-loading washing machine by cleaning the rubber door seal to reduce moisture and help prevent mould growth in the home.

How to Remove Mould from Your Washing Machine and Stop It Coming Back

Removing mould from a front-loading washing machine by cleaning the rubber door seal to reduce moisture and help prevent mould growth in the home.
Regular cleaning of your washing machine, especially the rubber door seal, detergent drawer and filter, can help prevent mould growth and reduce damp-related problems in the home.

Mould inside a washing machine is common, particularly in front-loading machines. It often develops in the rubber door seal, detergent drawer, filter and other areas where moisture and detergent residue collect.

For most people, a small amount of washing-machine mould is mainly an unpleasant cleaning problem. However, people living with aspergillosis, severe asthma, allergies or other long-term lung conditions may reasonably want to reduce avoidable mould exposure in the home.

The most effective approach is not only to remove visible mould, but also to keep the machine dry and clean enough to prevent it returning.

Key points

  • Mould grows where moisture, detergent residue and dirt remain inside the machine.
  • The rubber door seal and detergent drawer are the most common problem areas.
  • Use gentle cleaning methods that avoid spraying mould spores or strong chemicals into the air.
  • Never mix bleach with vinegar, acidic cleaners, ammonia or other cleaning products.
  • Leaving the door and detergent drawer open between washes can greatly reduce recurrence.

Why does mould grow inside washing machines?

Modern washing machines often use less water and lower washing temperatures. This saves energy, but it can also allow detergent residue, fabric conditioner, skin oils, dirt and moisture to build up inside the machine.

Mould is more likely to develop when:

  • the door is closed immediately after a wash;
  • wet laundry is left inside the drum;
  • mostly cool or eco washes are used;
  • too much detergent or fabric conditioner is added;
  • the rubber seal is not wiped or allowed to dry;
  • the detergent drawer or filter is rarely cleaned;
  • the machine is kept in a poorly ventilated room.

Where to check for mould

Mould may not always be immediately visible. Check the following areas carefully:

  • Rubber door seal: pull back the folds and inspect underneath.
  • Detergent drawer: remove it if possible and check the compartment behind it.
  • Drum: look around the door opening and drainage holes.
  • Filter: check the manufacturer’s instructions before opening it.
  • Drainage area: persistent odours may indicate residue or stagnant water deeper inside the machine.

Before you start cleaning

Check the washing machine manufacturer’s instructions first. Different manufacturers recommend different cleaning products, temperatures and maintenance programmes.

To reduce exposure while cleaning:

  • open a window or improve ventilation;
  • wear household cleaning gloves;
  • avoid leaning directly over mouldy areas;
  • use damp disposable cloths rather than dry brushing;
  • avoid scraping or scrubbing so vigorously that material is dispersed into the air;
  • ask someone else to clean the machine if mould exposure usually worsens your breathing.

Some people with aspergillosis or severe respiratory disease may choose to wear a well-fitting FFP2 or FFP3 mask during mould cleaning. A mask does not replace ventilation or careful cleaning methods.

How to clean mould from the rubber door seal

  1. Switch off the washing machine.
  2. Gently pull back the folds of the rubber seal.
  3. Remove any trapped lint, hair, tissues or other debris.
  4. Wipe the area using a damp cloth and a cleaning product approved by the machine manufacturer.
  5. Pay particular attention to the lower part of the seal, where water often collects.
  6. Use a clean damp cloth to remove any remaining cleaning product.
  7. Dry the seal thoroughly.

Black staining may remain even after mould has been removed. Persistent staining does not always mean that mould is still actively growing, but damaged or deeply contaminated seals may need replacing.

How to clean the detergent drawer

  1. Remove the drawer according to the manufacturer’s instructions.
  2. Wash it with warm water and washing-up liquid.
  3. Use a small brush for narrow areas, taking care not to flick residue into the air.
  4. Wipe the compartment where the drawer sits.
  5. Rinse and dry the drawer before replacing it.

Using too much detergent or fabric conditioner can encourage residue to collect in this area. Follow the dosing instructions for your detergent and local water hardness.

Cleaning the filter

Many washing machines have a filter behind a small panel near the bottom of the machine. This may collect lint, hair, coins and other debris.

Before opening it:

  • read the manufacturer’s instructions;
  • switch off and unplug the machine;
  • place towels or a shallow tray underneath, as water may escape;
  • allow hot water to cool before opening the filter.

Clean the filter, remove debris and replace it securely. A blocked or dirty filter can contribute to poor drainage and unpleasant smells.

Run a maintenance wash

After cleaning the visible parts of the machine, run the manufacturer’s drum-clean or maintenance programme.

If the machine does not have a dedicated cleaning cycle, the manufacturer may recommend an empty hot wash. Use only a cleaning product that is suitable for your particular machine.

Do not assume that adding more cleaner will work better. Excessive detergent or cleaning product may leave additional residue behind.

Avoid mixing cleaning chemicals

Important safety warning

Never mix bleach with vinegar, limescale remover, toilet cleaner, ammonia or other household cleaning products.

Mixing bleach with acidic products can release chlorine gas, which can cause serious breathing difficulties and may require urgent medical attention.

Use one product at a time, follow the label instructions and rinse surfaces before using any different product.

How to stop washing-machine mould coming back

Keeping the machine dry between washes is often more effective than repeatedly carrying out deep cleaning.

  • Remove laundry promptly when the cycle finishes.
  • Leave the washing-machine door slightly open between washes.
  • Leave the detergent drawer open so it can dry.
  • Wipe moisture from the door seal, particularly from the lower folds.
  • Use the correct amount of detergent.
  • Reduce or avoid fabric conditioner if residue repeatedly builds up.
  • Run the manufacturer’s maintenance cycle regularly.
  • Clean the drawer, seal and filter routinely.
  • Make sure the room is adequately ventilated.

How often should the machine be cleaned?

There is no single schedule suitable for every household. A machine used daily may need more frequent attention than one used only occasionally.

As a practical guide:

  • wipe and check the door seal every week or two;
  • clean the detergent drawer approximately once a month;
  • run a maintenance wash according to the manufacturer’s advice;
  • check the filter every few months, or sooner if drainage becomes slow or the machine smells.

Clean the machine sooner if you notice visible mould, slime, residue or a persistent musty smell.

When should the door seal be replaced?

Replacing the rubber door seal may be more effective than repeated cleaning if:

  • the seal is cracked, torn or misshapen;
  • mould is deeply embedded in the rubber;
  • water repeatedly collects because the seal is damaged;
  • the machine leaks;
  • a persistent smell remains after thorough cleaning.

A competent appliance engineer may be able to replace the seal without replacing the whole washing machine.

When might the washing machine need professional attention?

Consider contacting the manufacturer or an appliance engineer if:

  • the machine does not drain properly;
  • stagnant water remains inside;
  • the smell returns immediately after cleaning;
  • mould appears to be growing behind inaccessible panels;
  • the machine leaks;
  • the seal or internal pipework needs replacing.

Is washing-machine mould dangerous for people with aspergillosis?

Finding mould in a washing machine does not necessarily mean that your home contains unusually high levels of airborne mould. Washing machines are naturally damp environments, and small amounts of mould are common.

However, people with aspergillosis or other significant respiratory conditions may wish to take reasonable precautions, particularly when disturbing visible mould.

Try to avoid:

  • dry brushing;
  • scraping large mouldy areas;
  • using sprays that create a fine mist;
  • mixing cleaning chemicals;
  • remaining in a poorly ventilated room while strong products are being used.

If cleaning mould reliably causes coughing, wheezing, chest tightness or breathlessness, ask someone else to do the cleaning where possible.

When to seek medical advice

Seek medical advice if you develop a persistent worsening of respiratory symptoms after mould exposure, particularly if you have aspergillosis, severe asthma, bronchiectasis or another chronic lung condition.

Call 999 or seek urgent medical help if exposure to cleaning chemicals causes severe breathlessness, chest pain, confusion, collapse or difficulty speaking in full sentences.

Frequently asked questions

Can I use bleach in my washing machine?

Only use bleach if the washing-machine manufacturer states that it is safe for your model. Bleach can damage some rubber seals, metal parts and internal components.

Never mix bleach with vinegar or any other cleaning product.

Can I use vinegar?

Some manufacturers advise against regular vinegar use because concentrated acids may damage rubber seals or internal components. Check the instructions for your machine before using it.

Does a hot wash kill mould?

A hot maintenance wash may help reduce microorganisms and remove detergent residue, but it may not remove mould that is deeply embedded in a damaged rubber seal. Physical cleaning and drying are still important.

Should I replace the machine if there is mould in the seal?

Usually not. The seal can often be cleaned or replaced. Replacing the entire machine is generally only necessary if there is extensive inaccessible contamination, repeated drainage problems or the cost of repair is not economical.

Should I keep the door open all the time?

Leaving the door slightly open helps moisture evaporate. However, consider the safety of children and pets, who may climb into an open machine. Keep the laundry area secure where necessary.

Does washing at low temperatures cause mould?

Low-temperature washes can contribute to residue building up inside the machine, particularly if too much detergent or fabric conditioner is used. Regular maintenance cycles can help control this.

Related information

Always follow the cleaning and maintenance instructions supplied by the manufacturer of your washing machine.


Illustration showing how Xolair (omalizumab) treats allergic bronchopulmonary aspergillosis (ABPA) by blocking IgE antibodies and reducing allergic inflammation in the lungs.

Why Can an Asthma Drug Help ABPA? Understanding Xolair (Omalizumab)

Illustration showing how Xolair (omalizumab) treats allergic bronchopulmonary aspergillosis (ABPA) by blocking IgE antibodies and reducing allergic inflammation in the lungs.
Xolair (omalizumab) does not kill Aspergillus. Instead, it blocks IgE antibodies, helping to reduce the allergic inflammation that drives many symptoms of ABPA. It is often used alongside antifungal medicines and other treatments.

Originally published: 8 July 2026
Last reviewed: 8 July 2026

Many people diagnosed with Allergic Bronchopulmonary Aspergillosis (ABPA) are surprised when their specialist suggests Xolair (omalizumab).

"I thought Xolair was an asthma medication. How can it possibly help a fungal lung disease?"

It is a very reasonable question.

The answer is that ABPA is not simply an infection caused by Aspergillus. It is an allergic lung disease in which the immune system overreacts to the presence of Aspergillus in the airways.

Xolair does not kill the fungus. Instead, it helps calm the allergic immune response that drives many of the symptoms of ABPA.


Key Points

  • Xolair (omalizumab) is a biologic medicine originally developed for severe allergic asthma.
  • Many people with ABPA also have severe allergic asthma.
  • Omalizumab targets IgE, an antibody involved in allergic inflammation.
  • In the UK, omalizumab is usually prescribed through NHS severe asthma pathways, not because ABPA itself is a licensed indication.
  • Treating severe allergic asthma can also improve ABPA because the two conditions share important allergic immune pathways.
  • Biosimilar versions of omalizumab are now becoming available, which may make biologic treatment more accessible for eligible patients.

Understanding ABPA

Everyone breathes in Aspergillus spores every day.

For most people, this causes no illness. In people with ABPA, however, the immune system reacts too strongly. Instead of ignoring the spores, it launches an exaggerated allergic response.

This can cause:

  • airway inflammation
  • wheezing
  • coughing
  • breathlessness
  • excessive mucus production
  • repeated flare-ups
  • gradual lung damage if poorly controlled.

In many patients, the allergic response causes more problems than the fungus itself.

That is why doctors may treat both the amount of fungus in the airways and the immune system's overreaction to it.


What Does IgE Have To Do With ABPA?

One of the key parts of allergic disease is an antibody called Immunoglobulin E, usually shortened to IgE.

Think of IgE as part of the body's allergy alarm system.

In ABPA, the immune system produces IgE against Aspergillus. This can trigger immune cells to release chemicals that cause allergic inflammation. These chemicals narrow the airways, increase mucus production and attract other inflammatory cells, including eosinophils.

Doctors often measure total IgE because it is important in diagnosing and monitoring ABPA.


How Does Xolair Work?

Xolair (omalizumab) is a biologic medicine. Biologics are targeted treatments designed to block specific parts of the immune system.

Omalizumab attaches to free IgE antibodies before they can trigger the allergic cascade.

As a result:

  • allergic inflammation may be reduced
  • asthma symptoms may improve
  • flare-ups may become less frequent
  • some patients may be able to reduce oral steroid treatment
  • quality of life may improve.

Xolair does not kill Aspergillus.

Instead, it reduces the body's excessive allergic response to the fungus.


Why Was I Offered An Asthma Drug?

This is one of the most common questions patients ask.

Although ABPA is a distinct condition, many people with ABPA also have severe allergic asthma. The two conditions share many of the same allergic immune pathways, particularly those involving IgE.

In the UK, omalizumab is not currently licensed specifically for ABPA.

Many patients receive omalizumab because they meet NHS eligibility criteria for severe allergic asthma. When the allergic asthma improves, the ABPA may also improve because both conditions are driven by overlapping allergic inflammation.

In other words, the treatment is not aimed at killing Aspergillus. It is aimed at reducing the allergic inflammation that contributes to both severe asthma and ABPA.


Why Can't Everyone With ABPA Have Xolair?

This is an important question.

In the NHS, access to omalizumab is usually based on nationally agreed eligibility criteria for licensed conditions such as severe allergic asthma. A diagnosis of ABPA alone does not usually make someone eligible for omalizumab treatment.

This does not mean omalizumab cannot help some people with ABPA. It means that NHS prescribing is guided by licensing, NICE recommendations, commissioning arrangements and clinical judgement.

Your respiratory specialist will consider your asthma severity, ABPA history, IgE levels, previous treatments, steroid exposure, flare-up frequency and overall health when deciding whether a biologic medicine may be appropriate.


Why Aren't Antifungal Drugs Enough?

Antifungal medicines such as itraconazole or voriconazole reduce the amount of Aspergillus growing in the airways.

However, reducing the fungus does not always completely switch off the allergic immune response.

Different treatments target different parts of the disease:

Treatment Main purpose
Antifungal medicines Reduce the amount of Aspergillus
Corticosteroids Reduce widespread inflammation
Biologics such as omalizumab Target specific allergic pathways
Airway clearance Help remove mucus from the lungs

These treatments often work together rather than replacing one another.


Why Have Steroids Been Used For So Long?

For many years, oral corticosteroids such as prednisolone have been a main treatment for ABPA.

Steroids are often effective at controlling inflammation quickly, but prolonged or repeated courses can cause significant side effects, including:

  • weight gain
  • diabetes
  • osteoporosis
  • cataracts
  • mood changes
  • increased infection risk
  • adrenal suppression or adrenal insufficiency.

One reason biologics are important is that they may help some suitable patients reduce their need for long-term oral steroids under specialist supervision.


Does Xolair Help Everyone?

No.

Some patients experience major improvements. Others notice more gradual changes. A small number may gain little benefit and may be better suited to a different biologic medicine.

Published studies and specialist-centre experience suggest that some patients with ABPA treated with omalizumab may experience:

  • fewer exacerbations
  • better asthma control
  • reduced oral steroid requirements
  • improved quality of life.

Because ABPA is relatively uncommon, much of the evidence comes from case series, observational studies, smaller trials and systematic reviews rather than the very large trials often performed for common diseases.


Why Isn't Xolair Licensed Specifically For ABPA?

This can be confusing for patients.

Being "not licensed for ABPA" does not necessarily mean there is no evidence that omalizumab can help. It means that the medicine has not gone through the formal licensing process for ABPA as a specific indication.

Licensing a medicine for a new condition usually requires large, expensive clinical trials. ABPA is a relatively uncommon disease, which makes such studies difficult to organise and fund.

There is also less commercial incentive now that omalizumab biosimilars are becoming available. No single manufacturer may have a strong reason to fund large registration trials for an additional ABPA indication.

As a result, the scientific evidence and clinical experience have grown faster than the formal licensing process.


Why Is Omalizumab Back In The News?

Omalizumab itself is not new. It has been used for severe allergic asthma for more than twenty years.

What is new is the increasing availability of biosimilar omalizumab.

Biosimilars are highly similar versions of an existing biologic medicine. They must show comparable quality, safety and effectiveness before approval.

This matters because biologic medicines are expensive. Increased competition from biosimilars is expected to reduce costs over time.

Lower costs may improve access for patients who meet NHS eligibility criteria and may also increase research interest in biologic treatment for conditions such as ABPA.

It is important not to overpromise: biosimilars do not automatically mean that everyone with ABPA will be offered omalizumab. NHS access will still depend on eligibility criteria, clinical assessment and local pathways.


Are There Other Biologics?

Yes.

Omalizumab was the first biologic widely used in allergic asthma and has been used in selected patients with ABPA. Newer biologics target different parts of the allergic inflammatory pathway.

Depending on an individual's disease pattern, specialists may consider medicines such as:

  • mepolizumab
  • benralizumab
  • dupilumab
  • tezepelumab.

Research is continuing to determine which patients are most likely to benefit from each biologic.


Questions You May Wish To Ask Your Specialist

  • Why do you think omalizumab is appropriate for me?
  • Am I being considered for this because of severe allergic asthma, ABPA, or both?
  • How long before we know whether it is working?
  • Will I still need antifungal treatment?
  • Could this help reduce my oral steroid dose?
  • What side effects should I watch for?
  • Would another biologic be more suitable for my type of inflammation?

The Bottom Line

Xolair (omalizumab) was originally developed for severe allergic asthma, but it can also help some people with ABPA because ABPA is strongly driven by allergic immune inflammation.

In the NHS, omalizumab is usually prescribed through severe asthma pathways rather than because ABPA itself is a licensed indication.

It is not an antifungal drug and it is not a cure for ABPA. Instead, it is part of a modern treatment approach that may include antifungal medicines, airway clearance, corticosteroids, monitoring and biologic therapy in selected patients.

With biosimilar omalizumab becoming available and newer biologics continuing to emerge, treatment options for severe allergic lung disease are changing. For people living with ABPA, this is an important and rapidly developing area of care.


Related Articles


Heatwaves

We usually think of winter as being the worst season for respiratory conditions, but heatwaves can be just as dangerous – and they are becoming more frequent. Many people with aspergillosis have to juggle several long-term health conditions (e.g. COPD, diabetes, anxiety), so it is important to be well-prepared

Severe heat puts extra strain on the body and destabilises the core routines that keep a person well:

  • Harder to get good-quality sleep
  • Lack of appetite
  • Exercise is more tiring
  • Holidays & visiting family away from home


Air pollution


Humidity is often higher in the UK than other countries, so the heat feels worse

  • Humidity should be around 30-50%
  • Damp air can trap pollution like pollen, ozone and traffic fumes. Check the air quality before you go out on the DEFRA website
  • Damp conditions can encourage growth of mould, especially in bathrooms and kitchens that will take longer to dry out
  • Read more: Healthline,


Dehydration

  • Your urine should be the colour of pale straw – if it is darker, you need to drink more water
  • Sip water  throughout the day so that your body can absorb it gradually
  • Keep a jug of water in the fridge with a few slices of lemon, cucumber or a sprig of mint for variety
  • Freeze plenty of ice cubes before the heatwaves starts
  • Carry extra water on day trips and journeys – you may get stuck in a traffic jam or train delays
  • Salads and ice lollies help boost your water intake


  • Close the curtains on south-facing windows, or tape tin foil to the glass
  • Turn off any lights and electrical devices while not in use
  • Open windows in the morning and evenings, but close them if the heat outside becomes hotter than the air inside
  • Use a fan to blow air over ice cubes or a bottle of frozen water
  • Place a damp flannel on your neck and sit in front of a fan – the evaporation produces a strong cooling effect
  • Keep any water reservoirs and paper elements in air cooling devices clean otherwise they may grow mould over time


It is important to read the information leaflet for every medication you take, and ask your pharmacist for advice if you have any questions

  • Be VERY careful about sun exposure if you are taking voriconazole, as it can causes photosensitivity. Even short amounts of time in the sun can cause severe sunburn and blistering. Avoid direct sunlight as much as possible by staying in the shade and wearing long loose clothing. Don’t forget your feet!
  • Check each of your medications for the correct storage temperature. Be careful never to leave medication in a hot car.
  • If medication needs to be kept in the fridge (~4°C), put it on a shelf (the door changes temperature every time you open it). Ask your pharmacist for advice on using a cool pouch to carry medication on day trips
  • If medication must be kept at room temperature, do NOT put it in the fridge as it can damage the formulation (e.g. some antibiotics)
  • Be aware of any side-effects that may become worse in hot weather
    • Diuretics –> dehydration
    • Vomiting/diarrhoea –> dehydration
    • Nausea –> loss of appetite –> tablet absorption
  • Injected medications may absorb faster than usual
  • Carry your rescue inhaler (even if you rarely use it)


Swimming is a great way to keep cool

  • Outdoor water can contain harmful microbes that may be dangerous for  immunocompromised people. Check the water quality of UK beaches using the Swimfo tool produced by the Environment Agency. Be cautious about ‘wild swimming‘ in rivers or lakes, especially in urban or agricultural areas
  • Never jump into water if you don’t know how deep or cold it is. If you do experience cold water shock, try to float on your back and breathe steadily – you will recover within a couple of minutes
  • Be careful not to overdo it! It’s easy to use more energy than you expect, especially in cooler water. Take regular breaks and remember to reapply sunscreen. Bring a drink/snack in your bag and check your blood sugar regularly (if relevant). Warm up gradually and pace yourself. Consider bringing a buoyancy aid (e.g. flotation belt, kick board, pool noodle) to reduce the energy demand


ADRENAL INSUFFICIENCY affects some aspergillosis patients who take steroids for a long time

www.addisonsdisease.org.uk/hot-weather

  • Stay hydrated (bottled water often has very low sodium)
  • Carry salt tablets or salty snacks
  • If you feel tired and dizzy, you may need more of your medication
  • Build in plenty of rest time (even if it feels a bit boring)
  • Carry your emergency kit and card
  • If away from home, keep the phone number and postcode handy for where to get medical help
  • Be quick to seek help if you feel unwell in ANY way, even if it’s inconvenient


DIABETES is common among older people

www.diabetes.org.uk/about-diabetes/looking-after-diabetes/hot-weather

  • Injected insulin may be absorbed faster
  • Factor in changes in activity and food (maybe keep a diary)
  • Check your blood sugar more often (especially right before and after exercise)
  • Keep insulin cool and watch for cloudiness or brownish colour
  • Make sure friends and family know how to help you in case of a hypo


Vaccination protects people living with aspergillosis and other chronic lung diseases against serious respiratory infections.

Vaccinations for People Living with Aspergillosis

Vaccination protects people living with aspergillosis and other chronic lung diseases against serious respiratory infections.
Vaccination is an important part of staying well with aspergillosis. Seasonal flu, COVID-19, pneumococcal, RSV and shingles vaccines may help reduce the risk of serious respiratory infections. Always discuss your individual vaccination needs with your healthcare team.

First published: [add original date]
Last reviewed: July 2026

Vaccinations are an important part of staying well when you live with aspergillosis or another long-term lung condition. They cannot prevent aspergillosis itself, but they can reduce the risk of infections that may make breathing symptoms worse, trigger flare-ups, or lead to hospital admission.

International readers: This article explains why vaccination matters for people living with aspergillosis. Vaccine recommendations, availability and eligibility vary between countries. Where healthcare-system information is included, it refers to the UK unless otherwise stated. Always follow advice from your own healthcare team.

Key points

  • Vaccines do not prevent aspergillosis, but they can reduce the risk of serious infections that may worsen lung disease.
  • People with aspergillosis often also have asthma, bronchiectasis, COPD or immune system problems, which can make infections more serious.
  • Flu, COVID-19, pneumococcal, RSV and shingles vaccines may be relevant, depending on your age, health conditions and local guidance.
  • Some people need additional vaccines or vaccine-response testing as part of specialist immunology care.
  • If you take long-term steroids, biologics or other immune-suppressing medicines, ask which vaccines are suitable for you.

Why vaccination matters if you have aspergillosis

Many people living with aspergillosis already have lungs that are more vulnerable than usual. This may be because of asthma, bronchiectasis, COPD, previous infection, scarring, mucus plugging, cavities in the lung, or reduced lung function.

For this reason, an infection that is mild for one person can sometimes cause a much bigger setback for someone with aspergillosis. A respiratory infection may lead to increased breathlessness, more coughing, thicker sputum, a flare-up of asthma or COPD, or a chest infection that takes weeks to recover from.

Vaccination is one way to reduce this risk. It does not replace usual aspergillosis treatment, airway clearance, antifungal medication, inhalers or other care, but it can be an important part of protecting your lungs.

Which vaccines are most important?

The vaccines that matter most will depend on your age, diagnosis, immune system, medications, previous vaccine history and the country where you live. The vaccines below are commonly discussed for people with long-term lung disease or increased infection risk.

Influenza (flu) vaccine

For many people living with aspergillosis, the annual flu vaccine is one of the most important ways to reduce the risk of a serious winter chest infection.

Flu is not just a heavy cold. It can cause fever, severe tiredness, muscle aches and worsening breathing symptoms. In people with asthma, bronchiectasis, COPD or other lung disease, flu may trigger a flare-up or lead to pneumonia.

Because flu viruses change over time, the vaccine is updated regularly and is usually offered each year before the main flu season.

COVID-19 vaccine

COVID-19 can still cause serious illness in people who are older, immunosuppressed or living with chronic lung disease. Some people with aspergillosis may therefore be offered seasonal COVID-19 vaccination or booster doses.

Eligibility changes over time and differs between countries. If you are unsure whether you should receive a COVID-19 booster, ask your GP, pharmacist, respiratory specialist or local healthcare team.

Pneumococcal vaccine

Pneumococcal disease is caused by bacteria that can lead to pneumonia and, less commonly, serious infections such as bloodstream infection or meningitis.

This vaccine is particularly relevant for many people with chronic respiratory disease. People with aspergillosis may also have bronchiectasis, COPD, asthma, scarring or cavities in the lung, all of which can make bacterial chest infections more difficult to recover from.

If you are not sure whether you have had a pneumococcal vaccine, or whether your record is up to date, ask your GP surgery or specialist team.

RSV vaccine

Respiratory syncytial virus, usually called RSV, is a common respiratory virus. In many people it causes cold-like symptoms, but in older adults and people with lung disease it can cause more serious lower respiratory tract infection.

RSV vaccination is a newer area of adult vaccination. Some countries now recommend RSV vaccination for older adults or people at increased risk of severe respiratory illness.

If you are older or have chronic lung disease, it is worth asking whether RSV vaccination is recommended for you.

Shingles vaccine

Shingles is caused by reactivation of the chickenpox virus. It can cause a painful rash and may lead to long-lasting nerve pain.

The shingles vaccine reduces the risk of shingles and its complications. It may be particularly relevant for older adults and some people with weakened immune systems.

Additional vaccines for some people

Some people with aspergillosis also have other medical conditions that affect the immune system or increase their risk of certain infections. In these situations, your specialist may recommend additional vaccines as part of your care.

For example, some people with immune deficiencies, those without a functioning spleen, or people who have received a stem cell transplant may be advised to receive vaccines such as Haemophilus influenzae type b (Hib) or meningococcal vaccines. These vaccines are not routinely recommended for everyone with aspergillosis, but they may be appropriate for certain individuals.

If you have recurrent infections, your respiratory specialist or immunologist may also investigate how well your immune system responds to vaccines. In some cases, measuring antibody responses to vaccines such as the pneumococcal vaccine forms part of an assessment for possible antibody deficiency.

Travel vaccines may also be needed if you are visiting countries where certain infections are more common. If you are planning travel, ask for advice well in advance, especially if you are immunosuppressed.

Vaccines and steroids, biologics or immune-suppressing treatment

Some people with aspergillosis take medicines that affect the immune system, including:

  • oral steroids such as prednisolone or methylprednisolone
  • long-term or repeated courses of steroids
  • biologic medicines for severe asthma or ABPA
  • immune-suppressing medicines for other conditions
  • chemotherapy or transplant-related medicines

Most routine adult vaccines are not live vaccines and are generally safe for people with chronic lung disease. However, live vaccines may not be suitable for people who are significantly immunosuppressed.

Important: Do not stop steroids, antifungal treatment or biologic medicines just to have a vaccine unless your own doctor tells you to. If you are immunosuppressed, ask your GP, pharmacist or specialist team which vaccines are suitable and when they should be given.

UK NHS information

In the UK, vaccination eligibility is based on age, medical conditions, pregnancy, occupation and immune status. It can also change between seasonal campaigns.

People with chronic respiratory disease are commonly eligible for seasonal flu vaccination and may be eligible for other vaccines depending on their age, diagnosis and treatment. This may include COVID-19 boosters, pneumococcal vaccination, RSV vaccination or shingles vaccination.

Ask your GP surgery, pharmacist or specialist respiratory team whether your vaccination record is up to date. This is especially important if you have:

  • bronchiectasis, COPD, severe asthma or another long-term lung condition
  • chronic pulmonary aspergillosis (CPA)
  • allergic bronchopulmonary aspergillosis (ABPA)
  • recurrent chest infections
  • long-term steroid treatment
  • other immune-suppressing treatment
  • a known or suspected immune deficiency

Can vaccines make aspergillosis worse?

Vaccines do not cause aspergillosis. They do not contain Aspergillus and cannot give you a fungal infection.

Some people feel tired, achy or feverish for a short time after vaccination. This is usually a normal immune response and settles within a few days.

If you develop worsening breathlessness, chest pain, coughing blood, oxygen levels lower than usual, or symptoms that feel very different from your usual pattern, seek medical advice.

Should family members be vaccinated?

Vaccination is not only about protecting the individual. If you live with someone who is clinically vulnerable, keeping household vaccinations up to date can reduce the chance of bringing infections into the home.

This may be especially important for people who are immunosuppressed, older, or living with severe lung disease.

Questions to ask your healthcare team

At your next GP, pharmacist or specialist appointment, consider asking:

  • Am I eligible for the annual flu vaccine?
  • Am I eligible for a COVID-19 booster this season?
  • Have I had the correct pneumococcal vaccine?
  • Am I eligible for the RSV vaccine?
  • Am I eligible for the shingles vaccine?
  • Do any of my medicines affect which vaccines I can have?
  • Do I need any additional vaccines because of immune problems or recurrent infections?
  • Should my antibody response to any vaccine be checked?
  • Are any vaccines recommended before starting a new immune-suppressing treatment?

Frequently asked questions

Can I have vaccines while taking antifungal medication?

In most cases, antifungal medicines such as itraconazole, voriconazole, posaconazole or isavuconazole do not prevent vaccination. If you are unsure, ask your pharmacist, GP or specialist team.

Can I have more than one vaccine at the same appointment?

Some vaccines can be given at the same appointment, but this depends on the vaccine, your health and local guidance. Your GP surgery or pharmacist can advise.

Should I delay vaccination if I am unwell?

If you have a high temperature or are acutely unwell, you may be advised to wait until you have recovered. Mild cold symptoms do not always mean vaccination must be delayed, but check with the vaccinator if you are unsure.

What if I had a reaction to a vaccine before?

Tell the vaccinator before receiving any vaccine. Serious allergic reactions are rare, but your history should be checked carefully.

Can vaccines give me aspergillosis?

No. Vaccines do not contain Aspergillus and cannot give you aspergillosis.

When to seek medical advice urgently

Seek urgent medical help if you have:

  • severe or rapidly worsening breathlessness
  • chest pain
  • blue lips or confusion
  • coughing up blood
  • oxygen levels lower than usual, if you monitor them
  • signs of a severe allergic reaction after vaccination, such as swelling of the face or throat, wheezing, collapse or a widespread rash

Useful links

Related information

You may also find these guides helpful:

```

Summary

Vaccination is one of the simplest ways to reduce the risk of serious respiratory infection. For people living with aspergillosis, bronchiectasis, COPD, severe asthma or immune suppression, it is worth checking regularly that your vaccination record is up to date.

The medical reasons for vaccination are relevant internationally, but vaccine eligibility and availability vary between countries. Ask your GP, pharmacist, respiratory specialist or local healthcare team which vaccines are recommended for you.


Preparing for a Disability Assessment: A Practical Guide for People Living with Aspergillosis in UK

Originally published: August 2018
Last reviewed: July 2026

If you have been invited to attend a disability assessment, it is natural to feel anxious. Many people worry about saying the wrong thing, forgetting important information or not being believed.

The purpose of the assessment is not simply to confirm your diagnosis. Instead, it aims to understand how your health condition affects your daily life, including your ability to carry out everyday activities safely, reliably and repeatedly.

For people living with aspergillosis, symptoms such as breathlessness, fatigue, chronic cough, medication side effects and frequent infections can all have a significant impact on daily life, even if they are not always obvious to other people.

This guide explains how to prepare for your assessment and how to describe your symptoms clearly and honestly.


What is a disability assessment?

Several UK benefits and support schemes may involve an assessment of how your condition affects your daily life. These include:

  • Personal Independence Payment (PIP)
  • Adult Disability Payment (Scotland)
  • Employment and Support Allowance (ESA)
  • Universal Credit health assessments

The assessment is usually carried out by an independent healthcare professional working on behalf of the Department for Work and Pensions (DWP) or the relevant national authority.

The assessor is interested less in the name of your condition than in understanding how it affects your ability to manage everyday tasks.


Before your assessment

Good preparation can make the assessment less stressful and help ensure you provide an accurate picture of how your condition affects you.

You may find it helpful to gather:

  • recent clinic letters
  • hospital discharge summaries
  • lung function results, where available
  • CT scan reports if relevant
  • your current medication list
  • details of inhalers, nebulisers or oxygen therapy
  • letters from your GP or specialist nurse

Having these documents available can help you answer questions confidently and provide supporting evidence if requested.


Keep a symptom diary

Many people underestimate how much their condition affects them because they gradually adapt to living with it.

Keeping a diary for one or two weeks before your assessment can help you remember important details.

Record things such as:

  • how far you can walk before stopping
  • how often you become breathless
  • episodes of coughing or coughing up blood
  • levels of fatigue
  • sleep disturbance
  • days when you cannot leave the house
  • help you receive from family or friends

This provides real-life examples that are often easier to explain during the assessment.


Describe your worst days as well as your better days

Many long-term lung conditions fluctuate. Some days may be manageable, while others are much more difficult.

It is important to explain:

  • how often bad days occur
  • how long they last
  • what you cannot do during these periods

If your condition varies, explain what happens on both good and bad days rather than describing only how you feel on the day of the assessment.


Explain how your symptoms affect everyday life

Assessors are interested in the practical impact of your condition.

Rather than simply saying:

"I get breathless."

Explain what that means in daily life.

"I have to stop halfway up the stairs to catch my breath."

Instead of saying:

"I'm tired all the time."

You might explain:

"After having a shower I usually need to rest for an hour before I can prepare breakfast."

These practical examples help assessors understand the real impact of your condition.


Remember the symptoms people cannot see

Not all symptoms are visible.

People living with aspergillosis often experience:

  • severe fatigue
  • brain fog
  • poor concentration
  • chronic cough
  • disturbed sleep
  • medication side effects
  • anxiety about breathlessness or haemoptysis
  • recurrent infections

These symptoms can significantly affect daily living, even when you appear well during the assessment.


Be honest about the help you need

Many people naturally try to remain independent and may overlook the assistance they receive from others.

Think about whether family members or friends help you with:

  • shopping
  • housework
  • gardening
  • transport
  • preparing meals
  • managing medication
  • heavy lifting

Needing help occasionally is still important to mention.


Medication side effects matter too

Your symptoms are only part of the picture.

Treatments for aspergillosis and associated conditions may also affect daily life.

Examples include:

  • fatigue
  • nausea
  • light sensitivity
  • tremor
  • dizziness
  • sleep disturbance
  • frequent blood tests and hospital appointments

Explain how these affect your ability to work, travel or carry out everyday activities.


During the assessment

Try not to rush your answers.

If you do not understand a question, ask for it to be repeated or explained.

Answer honestly. Avoid both minimising and exaggerating your symptoms.

If you become upset or need to pause because of coughing or breathlessness, take your time. Assessors understand that some conditions make conversations difficult.


After the assessment

You may wish to request a copy of the assessment report once it has been completed.

If you disagree with the decision, you usually have the right to ask for a mandatory reconsideration and, if necessary, to appeal.

Many successful claims are awarded following reconsideration or appeal, so do not assume the first decision is always final.


Getting support

You do not have to manage the process alone.

Help may be available from:

  • Citizens Advice
  • local welfare rights advisers
  • disability charities
  • hospital benefits advisers where available
  • your GP or specialist team, who may be able to provide supporting medical evidence

Key points to remember

  • Prepare before your assessment.
  • Use real-life examples rather than general statements.
  • Describe both good days and bad days.
  • Include fatigue, medication side effects and invisible symptoms.
  • Be honest about the help you need.
  • If you disagree with the decision, remember that you may be able to request a review or appeal.

Further information

You may also find these articles helpful:


References